AYOLLARDA BACHADON BO‘YNI SARATONI PREKANSER HOLATLARINI ANIQLASHDA HPV SKRININGINING DIAGNOSTIK QIYMATI

Abdusamatova Vazira

Keywords: inson papillomavirusi, HPV, bachadon bo‘yni saratoni, prekansyer holat, CIN, skrining, HPV-DNK, genotiplash.

---

Abstract

Bachadon bo‘yni saratoni ayollar reproduktiv salomatligiga jiddiy xavf tug‘diruvchi onkologik kasalliklardan biri bo‘lib, uning rivojlanishida yuqori xavfli inson papillomavirusi (HPV) infeksiyasining persistent shakli asosiy etiologik omil hisoblanadi. Kasallikning o‘ziga xos jihati shundaki, invaziv saraton rivojlanishidan oldin bachadon bo‘yni epiteliyasida uzoq vaqt davomida aniqlanishi va davolanishi mumkin bo‘lgan prekansyer o‘zgarishlar yuzaga keladi. Mazkur maqolaning maqsadi ayollarda bachadon bo‘yni prekansyer holatlarini aniqlashda yuqori xavfli HPV skriningining diagnostik qiymatini baholash hamda HPV testi, sitologik tekshiruv va keyingi diagnostik bosqichlarning klinik o‘rnini tahlil qilishdan iborat. Tadqiqotda zamonaviy xalqaro klinik tavsiyalar, tizimli tahlillar va ilmiy adabiyotlar ma’lumotlari tahliliy yondashuv asosida o‘rganildi. Tahlil natijalari HPVga asoslangan skriningning asosiy afzalligi yuqori xavfli virus infeksiyasini hujayraviy morfologik o‘zgarishlar rivojlanishidan oldin aniqlash imkoniyati ekanligini ko‘rsatadi. HPV-musbat ayollarni genotip, sitologiya yoki boshqa triage usullari yordamida xavf guruhlariga ajratish ortiqcha kolposkopiyalarni kamaytirish bilan birga klinik jihatdan ahamiyatli prekansyer lezyonlarni o‘z vaqtida aniqlashga yordam beradi. HPV skriningini standartlashtirish bachadon bo‘yni saratonining ikkilamchi profilaktikasini takomillashtirishning muhim yo‘nalishlaridan biridir.

---

References

1. Arbyn, M., Smith, S. B., Temin, S., Sultana, F., Castle, P., & Collaboration on Self-Sampling and HPV Testing. (2018). Detecting cervical precancer and reaching underscreened women by using HPV testing on self samples: Updated meta-analyses. BMJ, 363, k4823. https://doi.org/10.1136/bmj.k4823. BMJ

2. Arbyn, M., Xu, L., Verdoodt, F., Cuzick, J., Szarewski, A., Belinson, J. L., Wentzensen, N., Gage, J. C., & Khan, M. J. (2017). Genotyping for human papillomavirus types 16 and 18 in women with minor cervical lesions: A systematic review and meta-analysis. Annals of Internal Medicine, 166(2), 118–127. https://doi.org/10.7326/M15-2735. PubMed

3. Chen, W., Zhang, X., Molijn, A., Jenkins, D., Shi, J., Quint, W., ... Qiao, Y. (2010). Performance of high-risk human papillomavirus DNA testing as a primary screen for cervical cancer: A pooled analysis of individual patient data from 17 population-based studies from China. The Lancet Oncology, 11(12), 1160–1171. https://doi.org/10.1016/S1470-2045(10)70256-4. ScienceDirect

4. Koliopoulos, G., Nyaga, V. N., Santesso, N., Bryant, A., Martin-Hirsch, P. P. L., Mustafa, R. A., Schünemann, H., Paraskevaidis, E., & Arbyn, M. (2017). Cytology versus HPV testing for cervical cancer screening in the general population. Cochrane Database of Systematic Reviews, 2017(8), CD008587. https://doi.org/10.1002/14651858.CD008587.pub2. Cochrane

5. Ronco, G., Dillner, J., Elfström, K. M., Tunesi, S., Snijders, P. J. F., Arbyn, M., Kitchener, H., Segnan, N., Gilham, C., Giorgi-Rossi, P., Berkhof, J., Peto, J., & Meijer, C. J. L. M. (2014). Efficacy of HPV-based